Abstract
SummarySerotonin 1A receptor selective agents have been developed throughout the world, but have different degrees of acceptance in different countries. Although buspirone has been marketed in the United States and Europe, positive results were not obtained for trials of buspirone in anxiety in Japan. Positive results were also not obtained for a related agent, ipsapirone, in Japan, although another related agent, tandospirone, has been demonstrated to show clinical efficacy in anxiety in Japanese studies. This may lead to the ultimate marketing of tandospirone for anxiety disorders in Japan.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
